These data support the recommendation that a TRK inhibitor is the preferred up-front systemic therapy for advanced lung cancers that harbor a TRK fusion regardless of programmed cell death-ligand 1 expression levels, in line with current clinical practice guidelines. This evidence concerns the gene TPM3 and lung carcinoma.